End-stage heart failure (HF) frequently needs continuous inotropic support in hospital and has high morbidity and mortality in absence of heart transplantation.
LivaNova PLC announced it received 510(k) clearance for extracorporeal membrane oxygenation (ECMO) from the FDA for LifeSPARC, the Company’s next-generation Advanced Circulatory Support (ACS) pump and controller system
This guideline covers identifying and caring for adults who are malnourished or at risk of malnutrition in hospital or in their own home or a care home.
LivaNova PLC launched its innovative arterial femoral cannula, Bi-Flow, designed to prevent limb ischemia during cardiac surgery. LivaNova Bi-Flow received...
Following the recent CE approval of the Solia S lead for LBBAP (Left Bundle Branch Area Pacing), Biotronik announces the world’s first and only complete CSP system, now fully CE-approved for Left Bundle Branch Area Pacing
Medtronic has completed its acquisition of HeartWare International, Inc., a leading innovator of less-invasive, miniaturized, mechanical circulatory support technologies (MCS)...
The clinical course of heart failure is characterised by progressive worsening of cardiac function and symptoms. Patients progress to a condition where traditional treatment is no longer effective and advanced therapies...
Duke Clinical Research Institute will serve as the coordinating center for the Phase III levosimendan study . Drs. John H....
St Jude Medical announced results from the SHIELD I (Coronary InterventionS in HIgh-Risk PatiEnts Using a Novel Percutaneous Left Ventricular...
LivaNova PLC announced its Bi-Flow Extracorporeal Membrane Oxygenation (ECMO) cannula earned CE Mark approval for ECMO ( Extracorporeal Membrane Oxygenation) procedures where femoral artery cannulation can be applied.